DOI QR코드

DOI QR Code

Efficacy and Safety of Trastuzumab Added to Standard Treatments for HER2-positive Metastatic Breast Cancer Patients

  • Zhu, Zhen-Li (Department of Public Health, Shantou University Medical College) ;
  • Zhang, Jun (Department of Public Health, Shantou University Medical College) ;
  • Chen, Mei-Lan (Department of Public Health, Shantou University Medical College) ;
  • Li, Ke (Department of Public Health, Shantou University Medical College)
  • Published : 2013.12.31

Abstract

Introduction: Trastuzumab, an HER2-targeting agents, has shown efficacy in metastatic HER2-positive breast cancer patients. Single-agent clinical trials have evaluated therapeutic regimens using trastuzumab for metastatic breast cancer patients. The aim of our study is to evaluate the efficacy and safety of trastuzumab in combination with chemotherapy or hormone therapy in HER2-positive metastatic breast cancer patients. Methods: A literature research was conducted in PubMed and to identify appropriate studies from relevant reviews. Randomized controlled trials comparing chemotherapy or hormone therapy regimens in combination with trastuzumab were eligible. Dadta on clinical outcomes, including safety, efficacy, and patient characteristics were collected. Results: Seven articles describing five trials were included in our systematic review and meta-analysis. Partners of trastuzumab included in trials were anthracycline, paclitaxel, docetaxel, anastrozole and letrozole. The addition of trastuzumab to chemotherapy improved the overall survival (HR=0.79, 95%CI 0.65-0.96), while to hormone therapy did not (HR=0.85 95%CI 0.56-1.30). All trastuzumab-containing regimens increased cardiac toxicity (RR=3.37, 95%CI 1.26-9.02) and grade III-IV adverse events. Conclusions: Our study supports the addition of trastuzumab to chemotherapy which is effective and tolerated for metastatic breast cancer with HER2+ patients. Of note, more adverse events will occur followed the use of trastuzumab, especially cardiac toxicity, with two treatment regimens.

References

  1. Andersson M, Lidbrink E, Bjerre K, et al (2011). Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2–positive breast cancer: The HERNATA Study. J Clin Oncol, 29, 264-71. https://doi.org/10.1200/JCO.2010.30.8213
  2. Baselga J, Eacute (2001). Herceptin(R) alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology, 61, 14-21.
  3. Burstein H, Lieberman G, Slamon DJ, et al (2005). Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol, 16, 1772-7. https://doi.org/10.1093/annonc/mdi371
  4. Chan A (2007). A review of the use of trastuzumab (Herceptin(R)) plus vinorelbine in metastatic breast cancer. Ann Oncol, 18, 1152-8. https://doi.org/10.1093/annonc/mdl476
  5. Coussens L, Yang-Feng TL, Yu-Cheng L, et al (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-9. https://doi.org/10.1126/science.2999974
  6. Cuadros M, Villegas R (2009). Systematic review of HER2 breast cancer testing. Appl Immunohistoche Mol Morphol, 17, 1-7. https://doi.org/10.1097/PAI.0b013e318169fc1c
  7. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  8. Egger M, Smith GD, Martin S, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  9. Eiermann W (2001). Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol, 12, S57-62. https://doi.org/10.1093/annonc/12.suppl_1.S57
  10. Ewer MS, O'Shaughnessy JA (2007). Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer, 7, 22-9. https://doi.org/10.3816/CBC.2007.n.017
  11. Gasparini GM, Gion M, Mariani L, et al (2007). Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Tr, 101, 355-65. https://doi.org/10.1007/s10549-006-9306-9
  12. Harris CA, Ward RL, Dobbins TA, et al (2011). The efficacy of HER2-targeted agents in metastatic breast cancer: a metaanalysis. Ann Oncol, 22, 1308-17. https://doi.org/10.1093/annonc/mdq593
  13. Higgins J, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  14. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557. https://doi.org/10.1136/bmj.327.7414.557
  15. Horner M, Ries L, Krapcho M, et al (2009). SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD.
  16. Huober J, Fasching PA, Barsoum M, et al (2012). Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer–results of the eLEcTRA trial. The Breast, 21, 27-33. https://doi.org/10.1016/j.breast.2011.07.006
  17. JPT CHH, Green S (2011). Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. The Cochrane Collaboration.
  18. Kaufman B, Mackey JR, Clemens MR, et al (2009). Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive, hormone receptor–positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol, 27, 5529-37. https://doi.org/10.1200/JCO.2008.20.6847
  19. Keefe DL (2002). Trastuzumab-associated cardiotoxicity. Cancer, 95, 1592-600. https://doi.org/10.1002/cncr.10854
  20. Mantel N, Haenszel W (2004). Statistical aspects of the analysis of data from retrospective studies of disease. The Challenge of Epidemiology: Issues and Selected Readings, 1, 533-53.
  21. Marty M, Cognetti F, Maraninchi D, et al (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol, 23, 4265-74. https://doi.org/10.1200/JCO.2005.04.173
  22. Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med, 151, 264-9. https://doi.org/10.7326/0003-4819-151-4-200908180-00135
  23. O'Shaughnessy JA, Vukelja S, Marsland T, et al (2004). Phase II study of trastuzumab plus gemcitabine in chemotherapypretreated patients with metastatic breast cancer. Clin Breast Cancer, 5, 142-7. https://doi.org/10.3816/CBC.2004.n.019
  24. Seidman AC, Hudis C, Pierri MK, et al (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol, 20, 1215-21. https://doi.org/10.1200/JCO.20.5.1215
  25. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
  26. Slamon DJ, Leyland-Jones B, Shak K, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med, 344, 783-92. https://doi.org/10.1056/NEJM200103153441101
  27. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  28. Valero V, Forbes J, Pegram MD, et al (2011). Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol, 29, 149-56. https://doi.org/10.1200/JCO.2010.28.6450
  29. Wardley AM, Pivot X, Morales-Vasquez F, et al (2010). Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol, 28, 976-83. https://doi.org/10.1200/JCO.2008.21.6531
  30. Yusuf S, Peto R, Lewis J, et al (1985). Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovas Dis, 27, 335-71. https://doi.org/10.1016/S0033-0620(85)80003-7

Cited by

  1. Inactivated Sendai Virus Strain Tianjin Induces Apoptosis in Human Breast Cancer MDA-MB-231 Cells vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.5023
  2. Benefit of Post-mastectomy Radiotherapy of the Supra-/infraclavicular Lymphatic Drainage Area in Breast Cancer Patients vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5557
  3. Patients with HER2-positive Early Breast Cancer Receiving Adjuvant Trastuzumab: Clinicopathological Features, Efficacy, and Factors Affecting Survival vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1643
  4. Recent Progress in HER2 Associated Breast Cancer vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2591
  5. Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis vol.11, pp.5, 2016, https://doi.org/10.3892/etm.2016.3095